KR20070052694A - 유전자 발현을 위한 세포-유형-특이적 패턴 - Google Patents

유전자 발현을 위한 세포-유형-특이적 패턴 Download PDF

Info

Publication number
KR20070052694A
KR20070052694A KR1020067015965A KR20067015965A KR20070052694A KR 20070052694 A KR20070052694 A KR 20070052694A KR 1020067015965 A KR1020067015965 A KR 1020067015965A KR 20067015965 A KR20067015965 A KR 20067015965A KR 20070052694 A KR20070052694 A KR 20070052694A
Authority
KR
South Korea
Prior art keywords
gene
cell
genes
expression
level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020067015965A
Other languages
English (en)
Korean (ko)
Inventor
엘리자베쓰 두프 스투아트
윌리암 와치스맨
다니엘 머콜라
마이클 맥크렐랜드
제시카 왕-로드리구에즈
데이비드 트레인
찰리스 씨. 베리
카렌 아덴
린다 와서맨
스테븐 구우디슨
이고르 클라캔스키
Original Assignee
더 리젠트스 오브 더 유니이버시티 오브 캘리포니아
시드니 킴멜 캔서 센터
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 리젠트스 오브 더 유니이버시티 오브 캘리포니아, 시드니 킴멜 캔서 센터 filed Critical 더 리젠트스 오브 더 유니이버시티 오브 캘리포니아
Publication of KR20070052694A publication Critical patent/KR20070052694A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/30—Detection of binding sites or motifs
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/50—Mutagenesis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Medical Informatics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
KR1020067015965A 2004-01-09 2005-01-07 유전자 발현을 위한 세포-유형-특이적 패턴 Ceased KR20070052694A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US53538204P 2004-01-09 2004-01-09
US60/535,382 2004-01-09
US53616304P 2004-01-12 2004-01-12
US60/536,163 2004-01-12

Publications (1)

Publication Number Publication Date
KR20070052694A true KR20070052694A (ko) 2007-05-22

Family

ID=34798852

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020067015965A Ceased KR20070052694A (ko) 2004-01-09 2005-01-07 유전자 발현을 위한 세포-유형-특이적 패턴

Country Status (4)

Country Link
US (1) US8781750B2 (enExample)
JP (2) JP2008504803A (enExample)
KR (1) KR20070052694A (enExample)
WO (1) WO2005068664A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025054611A1 (en) * 2023-09-08 2025-03-13 The Trustees Of Princeton University Systems and methods for predicting high resolution cell-type-specific gene transcription and applications thereof

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005068664A2 (en) 2004-01-09 2005-07-28 The Regents Of The University Of California Cell-type-specific patterns of gene expression
US20120258442A1 (en) 2011-04-09 2012-10-11 bio Theranostics, Inc. Determining tumor origin
JP5690039B2 (ja) 2004-06-04 2015-03-25 バイオセラノスティクス インコーポレイテッドＢｉｏｔｈｅｒａｎｏｓｔｉｃｓ，Ｉｎｃ． 腫瘍の同定
CN101297045A (zh) * 2005-06-03 2008-10-29 阿威亚拉德克斯股份有限公司 肿瘤和组织的鉴定
JP2007295822A (ja) * 2006-04-28 2007-11-15 Kusakabe Bio-Medical Research Laboratory Inc 卵巣腫瘍のシスプラチン耐性マーカー
US7702468B2 (en) 2006-05-03 2010-04-20 Population Diagnostics, Inc. Evaluating genetic disorders
US10522240B2 (en) 2006-05-03 2019-12-31 Population Bio, Inc. Evaluating genetic disorders
KR100740582B1 (ko) * 2006-09-27 2007-07-19 한국과학기술연구원 가스크로마토그래피-질량분석기를 이용한 두 생체시료군 간대사체 차별성 분석 방법
CN101932602B (zh) * 2007-06-27 2017-05-24 新加坡国立大学 用于Artemin及相关配体的多肽和多核苷酸，及其使用方法
CN101802226A (zh) * 2007-09-17 2010-08-11 皇家飞利浦电子股份有限公司 分析卵巢癌病症的方法
US8153777B2 (en) * 2008-11-04 2012-04-10 Idera Pharmaceuticals, Inc. Modulation of toll-like receptor 5 expression by antisense oligonucleotides
WO2010062960A2 (en) 2008-11-26 2010-06-03 Cedars-Sinai Medical Center METHODS OF DETERMINING RESPONSIVENESS TO ANTI-TNFα THERAPY IN INFLAMMATORY BOWEL DISEASE
EP2370813A4 (en) * 2008-12-04 2012-05-23 Univ California MATERIALS AND METHODS FOR DIAGNOSIS AND PRESENTATION OF PROSTATE CANCER
GB0903026D0 (en) * 2009-02-23 2009-04-08 Glaxosmithkline Biolog Sa Novel method
WO2011116244A2 (en) * 2010-03-17 2011-09-22 Cedars-Sinai Medical Center Methods of diagnosing and treating conditions associated with metabolic clearance rate of insulin
US8728731B2 (en) * 2010-03-22 2014-05-20 Laboratory Corporation Of America Holdings Mutations associated with cystic fibrosis
JP2013532482A (ja) 2010-07-27 2013-08-19 ジェノミック ヘルス， インコーポレイテッド 遺伝子発現を用いた前立腺癌の予後を定量化する方法
DK2601609T3 (en) 2010-08-02 2017-06-06 Population Bio Inc COMPOSITIONS AND METHODS FOR DISCOVERING MUTATIONS CAUSING GENETIC DISORDERS
EA201391074A1 (ru) 2011-01-25 2013-12-30 Олмак Дайэгностикс Лимитед Профили экспрессии генов рака толстой кишки и способы применения
US9589099B2 (en) 2011-07-21 2017-03-07 The Chinese University Of Hong Kong Determination of gene expression levels of a cell type
CA2851388C (en) 2011-10-10 2023-11-21 The Hospital For Sick Children Methods and compositions for screening and treating developmental disorders
DK2773779T3 (da) 2011-11-04 2020-11-23 Population Bio Inc Fremgangsmåder og sammensætninger til diagnosticering, prognose og forebyggelse af neurologiske tilstande
US8632827B2 (en) 2011-12-13 2014-01-21 Avon Products, Inc Modulation of thymosin beta-4 in skin
EP2812452B1 (en) 2012-02-09 2020-05-27 Population Bio, Inc. Methods and compositions for screening and treating developmental disorders
US20140024546A1 (en) * 2012-05-01 2014-01-23 Synapdx Corporation Systems and methods for normalizing gene expression profiles of biological samples having a mixed cell population
CN104769430B (zh) * 2012-07-10 2018-12-14 尼平蓝山地方医疗区 流感中的风险分层
US9976180B2 (en) 2012-09-14 2018-05-22 Population Bio, Inc. Methods for detecting a genetic variation in subjects with parkinsonism
WO2014052855A1 (en) 2012-09-27 2014-04-03 Population Diagnostics, Inc. Methods and compositions for screening and treating developmental disorders
WO2014093053A1 (en) * 2012-12-11 2014-06-19 Avon Products, Inc. Modulation of thymosin beta-4 in skin
US10633449B2 (en) 2013-03-27 2020-04-28 Cedars-Sinai Medical Center Treatment and reversal of fibrosis and inflammation by inhibition of the TL1A-DR3 signaling pathway
RS62529B1 (sr) 2013-07-11 2021-11-30 Modernatx Inc Kompozicije koje sadrže sintetičke polinukleotide koji kodiraju proteine povezane sa crispr i sintetičke sgrnk i postupci upotrebe
EP3022295A4 (en) 2013-07-19 2017-03-01 Cedars-Sinai Medical Center Signature of tl1a (tnfsf15) signaling pathway
CN103757028B (zh) * 2014-01-23 2015-09-09 南京医科大学 Osbpl2突变型基因、其鉴定方法和检测试剂盒
WO2015120482A2 (en) * 2014-02-10 2015-08-13 Baylor College Of Medicine Recurrent fusion genes identified in high-grade serous ovarian carcinoma
WO2016036403A1 (en) 2014-09-05 2016-03-10 Population Diagnostics Inc. Methods and compositions for inhibiting and treating neurological conditions
JP6403260B2 (ja) * 2014-11-21 2018-10-10 学校法人日本大学 前立腺癌の判定、治療選択方法、予防又は治療剤
CN104611430A (zh) * 2015-01-26 2015-05-13 钱学庆 一种人类尿液中tmprss2-erg基因检测方法和引物
WO2017095960A1 (en) * 2015-11-30 2017-06-08 Synthetic Genomics, Inc. Compositions and methods for expressing genes in algae
WO2017161342A1 (en) 2016-03-17 2017-09-21 Cedars-Sinai Medical Center Methods of diagnosing inflammatory bowel disease through rnaset2
WO2018094469A1 (en) * 2016-11-24 2018-05-31 The Council Of The Queensland Institute Of Medical Research Determining a cancer prognosis
US10240205B2 (en) 2017-02-03 2019-03-26 Population Bio, Inc. Methods for assessing risk of developing a viral disease using a genetic test
JP7401432B2 (ja) 2017-12-01 2023-12-19 エンコーデッド セラピューティクス， インコーポレイテッド 操作されたｄｎａ結合タンパク質
EP3814521A4 (en) 2018-06-29 2022-07-27 The Jackson Laboratory SPLICING VARIANTS FOR BREAST CANCER
WO2020033700A1 (en) 2018-08-08 2020-02-13 Pml Screening, Llc Mathods for assessing the risk of developing progressive multifocal leukoencephalopathy caused by john cunningham virus by genetic testing
CN109593848B (zh) * 2018-11-08 2020-07-10 浙江大学 一种肿瘤相关序列、长链非编码rna及其应用
GB2582665B (en) * 2019-03-29 2021-12-29 Advanced Risc Mach Ltd Feature dataset classification
AU2021271317A1 (en) 2020-05-15 2023-01-19 Crispr Therapeutics Ag Messenger RNA encoding Cas9 for use in genome-editing systems
WO2022246204A2 (en) * 2021-05-21 2022-11-24 Ionis Pharmaceuticals, Inc. Compounds for reducing ptbp1 expression
WO2023076895A2 (en) * 2021-10-25 2023-05-04 University Of Cincinnati Molecular therapeutics for the treatment of hypertrophic cardiomyopathy and heart failure associated with mybpc3 gene mutations
AU2022393594A1 (en) * 2021-11-18 2024-05-30 Resonance Health Analysis Services Pty Ltd Method for treating cyclophilin b associated diseases
CN119296651B (zh) * 2024-09-19 2025-09-19 新疆维吾尔自治区人民医院 胸主动脉夹层关键细胞类型及亚型的分类方法及装置

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002059373A2 (en) * 2001-01-23 2002-08-01 Irm, Llc Genes overexpressed in prostate disorders as diagnostic and therapeutic targets
JP2005505746A (ja) * 2001-02-02 2005-02-24 ダナ−ファーバー キャンサー インスチチュート インコーポレーテッド レアイベント検出システム
DE10159404A1 (de) * 2001-12-04 2003-06-26 Arevia Gmbh Verfahren zur Analyse von Gewebeproben
AU2002953327A0 (en) * 2002-12-12 2003-01-09 Monash University Methods of diagnosing prognosing and treating activin associated diseases and conditions
WO2005028677A2 (en) * 2003-05-07 2005-03-31 Agilent Technologies, Inc. Systems and methods for determining cell type composition of mixed cell populations using gene expression signatures
WO2005068664A2 (en) 2004-01-09 2005-07-28 The Regents Of The University Of California Cell-type-specific patterns of gene expression

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025054611A1 (en) * 2023-09-08 2025-03-13 The Trustees Of Princeton University Systems and methods for predicting high resolution cell-type-specific gene transcription and applications thereof

Also Published As

Publication number Publication date
WO2005068664A2 (en) 2005-07-28
US20060292572A1 (en) 2006-12-28
US8781750B2 (en) 2014-07-15
JP2011229522A (ja) 2011-11-17
JP2008504803A (ja) 2008-02-21
WO2005068664A3 (en) 2006-04-27

Similar Documents

Publication Publication Date Title
US8781750B2 (en) Cell-type-specific patterns of gene expression
Olsson et al. CD44 isoforms are heterogeneously expressed in breast cancer and correlate with tumor subtypes and cancer stem cell markers
JP6144695B2 (ja) タキサン療法を用いて乳癌を処置する方法
EP2114990B9 (en) Method for predicting the response of NSCLC-patients to treatment by an EGFR-TK inhibitor
CN105473772A (zh) 预后分类与治疗腺体癌症的方法
CA2745961A1 (en) Materials and methods for determining diagnosis and prognosis of prostate cancer
Schneider et al. Identification and meta‐analysis of a small gene expression signature for the diagnosis of estrogen receptor status in invasive ductal breast cancer
WO2013052480A1 (en) Marker-based prognostic risk score in colon cancer
MX2010014280A (es) Distintivos y determinantes asociados con metástasis y método para utilizarlos.
US11680298B2 (en) Method of identifying risk of cancer and therapeutic options
CN104583422A (zh) 标志物在诊断和治疗前列腺癌中的用途
WO2008073177A2 (en) Expression profiles associated with irinotecan treatment
WO2011106709A2 (en) Epithelial biomarkers for cancer prognosis
US10087489B2 (en) Biomarkers and uses thereof in prognosis and treatment strategies for right-side colon cancer disease and left-side colon cancer disease
Li et al. Identification of novel characteristic biomarkers and immune infiltration profile for the anaplastic thyroid cancer via machine learning algorithms
Ohara et al. The evolution of metastatic upper tract urothelial carcinoma through genomic-transcriptomic and single-cell protein markers analysis
US20140100188A1 (en) Phenotyping tumor-infiltrating leukocytes
Cui et al. Regulation of gene expression in ovarian cancer cells by luteinizing hormone receptor expression and activation
Ceolin et al. Effect of 3′ UTR RET variants on RET mRNA secondary structure and disease presentation in medullary thyroid carcinoma
EP2550534B1 (en) Prognosis of oesophageal and gastro-oesophageal junctional cancer
CN110573629A (zh) 用于诊断早期胰腺癌的方法和试剂盒
Chen et al. Functional characterization of DLK1/MEG3 locus on chromosome 14q32. 2 reveals the differentiation of pituitary neuroendocrine tumors
Bosquet et al. Comparison of gene expression patterns between avian and human ovarian cancers
US20220228218A1 (en) Clinical and Molecular Prognostic Markers for Liver Transplantation
WO2020085937A1 (ru) Тест-система для предсказания результативности лечения онкобольных препаратом бевацизумаб (авастин)

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20060808

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20100107

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20110726

Patent event code: PE09021S01D

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

Comment text: Final Notice of Reason for Refusal

Patent event date: 20120919

Patent event code: PE09021S02D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20121203

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20120919

Comment text: Final Notice of Reason for Refusal

Patent event code: PE06011S02I

Patent event date: 20110726

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I